1. In Vivo
  2. >>Business Strategy

Cytyc and Digene Strike a Deal

Both Cytyc and Digene have hurdles to overcome. Skeptics fear that Cytyc, which has FDA approval for its monolayer sampling technology for cervical cancer screening, may never be more than a one-product company. And Digene, lacking sufficient sales and marketing presence in clinicians' offices, is progressing slower than many had hoped it would; it still has to clearly define the role of HPV (human papilloma virus) in cervical cancer detection and its utility as a broad screen versus what experts call "a triage tool." By entering into an exclusive agreement, the companies hope to address these issues.

Things couldn't be rosier for Cytyc Corp. Nearly five years after receiving FDA approval of its ThinPrepmonolayer sampling technology, the company is well on its way to becoming the standard of care in cervical cancer screening as an alternative to the conventional Pap smear. It has limited competition, increasingly satisfactory reimbursement, and solid profits. Its FDA-approved indication that ThinPrep is better than the conventional Pap smear at detecting cervical cancer is supported by accumulating scientific data. Wall Street, after hemming and hawing a bit over Cytyc's huge SG&A expenses, loves the story [A#1998800093.

Things are going well, albeit on a smaller scale, for Digene Corp. , also a successful diagnostic start-up, with...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business Strategy

Turning Defense Into Attack: Snapshots Of A Changing Medtech Market And How To Respond

 
• By Ashley Yeo

Against a backdrop of shifting trade policies, the end of multilateral market approaches and renewed focus on supply chain resilience, medtechs are doubling down on innovation in products and processes, and keeping unmet needs and outcomes in the center of the target.

AI Agents Set To Reshape Biopharma’s Workforce And Operations

 
• By David Wild

While biopharma companies experiment with genAI, agentic AI is rapidly shifting the work paradigm towards one of autonomous digital workers that can handle entire process flows.

Mapping Biopharma’s AI Strategy: From Custom Datasets to Foundation Models

 
• By David Wild

Biotech companies are pursuing diverse AI strategies beyond expensive custom data generation: foundation model fine-tuning, data-efficient computational methods and targeted proprietary datasets. In Vivo takes a look at some examples.

Late-Stage GLP-1 Drug Trials Outside The Cardiometabolic Space

 
• By David Wild

A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.

More from In Vivo

EU Medtech Outlook: The View From MedTech Europe Experts

 
• By Ashley Yeo

MedTech Forum 2025 was less MDR-focused than in previous years, as macro issues and exogenous threats were forced further into the center of medtech business thinking.

‘Confident In Lorundrostat’s Promise’: Mineralys CEO Talks Trials And Next Steps

 
• By Sushmita Panda

In a conversation with In Vivo, CEO Jon Congleton discusses Mineralys’s data-rich journey toward an NDA filing, the significance of recent trial wins and how its candidate may offer a dual benefit in blood pressure and renal protection.

BioBytes: Qubit Pharmaceuticals Unveils Quantum AI Model For Drug Discovery

 
• By David Wild

Qubit Pharmaceuticals and Sorbonne University launched a quantum AI model that could slash drug synthesis requirements and enable exploration of previously undruggable targets.